Company news

Neuroscientific Biopharmaceuticals Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

NSB partners with Linear Research for Phase I Clinical Study

June 22, 2021

R&D Tax Rebate Received

May 31, 2021

Update on Pivotal Ocular Safety Studies

May 4, 2021

Appendix 4C - quarterly

April 29, 2021

Manufacturing Update

April 27, 2021

Key Executive Appointments to Support Clinical Studies

March 30, 2021

NSB to investigate treatment for post-COVID Fibrosis

November 20, 2020

Strategic Placement to AlphaSwiss Partners

November 11, 2020

Appendix 4E and Annual Report

August 28, 2020

Updated Appendix 4C

August 11, 2020

Full Report from Multiple Sclerosis Study

August 3, 2020

EmtinB Positive Results in MS

July 13, 2020

Final Report received for Glaucoma Study

May 4, 2020

Positive Results in MS Study

March 17, 2020

Positive Results in Glaucoma Pig Model

March 10, 2020

Additional US Patent granted

January 21, 2020

CVN Model Indicates Neuroprotective Properties of EmtinB

December 5, 2019

NSB - Company Update

December 1, 2019

AGM Address

November 28, 2019

EmtinB Can Become a Revolutionary Treatment for Glaucoma

September 30, 2019

NSB Receives R&D Advanced Overseas Finding

September 1, 2019

NSB - FInal Data Received from Spinal Cord Injury Model

July 31, 2019

NSB - Breakthrough results from Spinal Cord Injury Model

July 2, 2019

Appendix 4D & Half-Year Financial Statements

February 25, 2019

Non-Renounceable Issue Prospectus

November 9, 2018

NSB Research Collaboration

September 20, 2018

NSB - Contract Research Agreement

September 6, 2018

Pause In Trading

September 5, 2018

Preliminary Final Report

August 31, 2018

ASX Notice - Admission to Official List

July 25, 2018

← Newer news releases

Decks

The 5 newest of 28 decks. Every deck is listed under its year.